Cargando…
A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors
SIMPLE SUMMARY: Fms-like tyrosine kinase type III (FLT3) inhibitors have been shown to induce significant clinical responses in patients with acute myeloid leukemia (AML) harboring FLT3 mutations. Responses to monotherapy and combination regimens are typically incomplete and transient, prompting the...
Autores principales: | Richardson, Gary Edward, Al-Rajabi, Raed, Uprety, Dipesh, Hamid, Anis, Williamson, Stephen K., Baranda, Joaquina, Mamdani, Hirva, Lee, Ya-Li, Nitika, Li, Li, Wang, Xingli, Dong, Xunwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177510/ https://www.ncbi.nlm.nih.gov/pubmed/37174019 http://dx.doi.org/10.3390/cancers15092553 |
Ejemplares similares
-
Association of Neutrophil, Platelet, and Lymphocyte Ratios with the Prognosis in Unresectable and Metastatic Pancreatic Cancer
por: Allen, Jessica, et al.
Publicado: (2020) -
Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis
por: Kasi, Anup, et al.
Publicado: (2020) -
Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2020) -
Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy
por: Hentzen, Stijn, et al.
Publicado: (2023) -
Breve historia de Cartagena 1501-1901 /
por: Lemaitre Román, Eduardo, 1914-1994
Publicado: (1983)